We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Get help to classify herbal medicines, vitamins, food preparations, supplements and tonics for import and export.
Check the tariff classification for a defined daily dose of active substances.
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Get help to classify organic chemicals that contain certain permitted additives or can be dissolved in water, for import and export.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Exeltis UK Limited has informed the MHRA regarding an inconsistency in the Patient Information Leaflet (PIL) packaged in cartons of the specified batches of Gepretix 100mg capsules.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Guidance for living safely with respiratory infections, including coronavirus (COVID-19).
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includes information on a recent National Patient Safety Alert...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Comply with good manufacturing practice (GMP) and good distribution practice (GDP), and prepare for an inspection.
Information about how many laptops, and tablets and 4G routers we have delivered or dispatched to local authorities, and academy trusts and FE colleges.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Pharmacy, prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
With an innovative adherence support tool among HIV-infected tuberculosis patients in Karnataka, India
Max Remedies has identified an infrequent printing error relating to the Braille text printed on the cartons of various batches of this product.
Information on depleted uranium (DU) including what it is, its uses, health effects and protection from exposure.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).